Coherus Oncology (CHRS) Projected to Post Earnings on Monday

Coherus Oncology (NASDAQ:CHRS) will likely be posting its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect the company to announce earnings of ($0.2633) per share and revenue of $14.3410 million for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Monday, May 11, 2026 at 5:00 PM ET.

Coherus Oncology (NASDAQ:CHRS) last announced its quarterly earnings results on Monday, March 9th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). The business had revenue of $12.75 million for the quarter, compared to analyst estimates of $14.09 million. Coherus Oncology had a negative return on equity of 860.29% and a net margin of 398.42%. On average, analysts expect Coherus Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Coherus Oncology Stock Performance

CHRS stock traded up $0.01 during mid-day trading on Monday, hitting $1.81. 98,133 shares of the company were exchanged, compared to its average volume of 1,896,499. Coherus Oncology has a 1-year low of $0.71 and a 1-year high of $2.62. The company has a current ratio of 1.47, a quick ratio of 1.45 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $279.75 million, a PE ratio of 1.24 and a beta of 1.01. The business has a 50 day simple moving average of $1.73 and a 200-day simple moving average of $1.63.

Analysts Set New Price Targets

Several research firms have recently issued reports on CHRS. Wall Street Zen raised shares of Coherus Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Weiss Ratings raised Coherus Oncology from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, April 22nd. Finally, Oppenheimer started coverage on shares of Coherus Oncology in a research report on Thursday, January 22nd. They set an “outperform” rating and a $10.00 price target on the stock. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Coherus Oncology presently has an average rating of “Moderate Buy” and an average price target of $7.00.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Quarry LP purchased a new position in shares of Coherus Oncology in the third quarter worth about $26,000. Blair William & Co. IL bought a new stake in Coherus Oncology in the fourth quarter valued at $27,000. BNP Paribas Financial Markets increased its position in Coherus Oncology by 108.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 13,832 shares during the period. Corient Private Wealth LLC lifted its position in shares of Coherus Oncology by 20.0% in the 2nd quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 10,000 shares during the period. Finally, Jane Street Group LLC bought a new stake in shares of Coherus Oncology during the 2nd quarter valued at about $46,000. 72.82% of the stock is owned by hedge funds and other institutional investors.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.